A new trading day began on Friday, with Nurix Therapeutics Inc (NASDAQ: NRIX) stock price down -4.80% from the previous day of trading, before settling in for the closing price of $18.97. NRIX’s price has ranged from $8.18 to $22.50 over the past 52 weeks.
Healthcare Sector giant saw their annual sales slid by -38.86% over the last five years. Meanwhile, its annual earnings per share averaged -5.67%. With a float of $99.81 million, this company’s outstanding shares have now reached $101.37 million.
Nurix Therapeutics Inc (NRIX) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Nurix Therapeutics Inc is 1.53%, while institutional ownership is 82.83%. The most recent insider transaction that took place on Dec 18 ’25, was worth 67,314. In this transaction Chief Legal Officer of this company sold 3,760 shares at a rate of $17.90, taking the stock ownership to the 50,897 shares. Before that another transaction happened on Dec 18 ’25, when Company’s Officer proposed sale 7,520 for $18.21, making the entire transaction worth $136,939.
Nurix Therapeutics Inc (NRIX) Recent Fiscal highlights
In its latest quarterly report, released on 11/30/2024, the company reported earnings of -0.75 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.83 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -5.67% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -3.36% during the next five years compared to -38.86% drop over the previous five years of trading.
Nurix Therapeutics Inc (NASDAQ: NRIX) Trading Performance Indicators
Here are Nurix Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.35. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 21.88.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.97, a number that is poised to hit -0.88 in the next quarter and is forecasted to reach -3.33 in one year’s time.
Technical Analysis of Nurix Therapeutics Inc (NRIX)
As of the previous 9 days, the stock’s Stochastic %D was 45.87%.
During the past 100 days, Nurix Therapeutics Inc’s (NRIX) raw stochastic average was set at 68.96%, which indicates a significant increase from 25.83% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.82 in the past 14 days, which was higher than the 0.78 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $15.79, while its 200-day Moving Average is $11.94. Now, the first resistance to watch is $18.77. This is followed by the second major resistance level at $19.49. The third major resistance level sits at $19.94. If the price goes on to break the first support level at $17.60, it is likely to go to the next support level at $17.15. Now, if the price goes above the second support level, the third support stands at $16.43.
Nurix Therapeutics Inc (NASDAQ: NRIX) Key Stats
With a market capitalization of 1.83 billion, the company has a total of 76,883K Shares Outstanding. Currently, annual sales are 54,550 K while annual income is -193,570 K. The company’s previous quarter sales were 7,890 K while its latest quarter income was -86,420 K.
